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Urinary and renal interstitial concentrations of TNF- increase
prior to the rise in albuminuria in diabetic rats
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Urinary and renal interstitial concentrations of TNF- increase
prior to the rise in albuminuria in diabetic rats.
Background. The development of diabetic nephropathy has
been linked to the release of vasoactive hormones and growth
factors. Currently the role of inflammatory cytokines in this
pathogenic process is not clear.
Methods. We utilized the microdialysis technique to monitor
early changes in tumor necrosis- (TNF-) levels in the renal
interstitial fluid and urine of conscious Sprague-Dawley rats
(N  8) before and after induction of diabetes with streptozo-
tocin (STZ). Measurement of the urinary albumin excretion
(UAE) was utilized to monitor the development and progres-
sion of diabetic nephropathy.
Results. UAE increased from 0.56  0.20 g/min to 8.14 
2.98 g/min 17 days after induction of diabetes (P  0.01).
Renal interstitial fluid TNF- increased from 11.96  5.32
pg/mL at baseline to 45.02 11.69 pg/mL 5 days after induction
of diabetes (P  0.03). Renal interstitial fluid TNF- levels
remained elevated throughout the remainder of the study pe-
riod. Urinary TNF- also increased significantly compared to
baseline 3 days after induction of diabetes (294.18  36.94
pg/mL vs. 16.05  6.07 pg/mL, P  0.002). There was a second
significant rise in urinary TNF- concentration to 638.16 
36.94 pg/mL 21 days after induction of diabetes (P  0.001).
Serum TNF- levels were undetectable before STZ injection
and remained undetectable by the end of the study. Urinary
and renal interstitial fluid TNF- in the control rats (N  5)
did not change throughout the study.
Conclusion. We found an early rise in renal TNF- levels
after induction of diabetes with STZ, which precedes the rise
in UAE by about 2 weeks. These findings suggest a possible
contribution of TNF- in the complicated pathogenic process
resulting in microalbuminuria in diabetes.
Diabetes mellitus is the most common cause of end-
stage renal disease (ESRD) in the United States, respon-
sible for more than 40% of cases at initiation of renal
replacement therapy. Glomerular hyperfiltration and hy-
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pertrophy and, later on, thickening of the glomerular
and tubular basement membranes and mesangial expan-
sion are among the pathologic changes seen in the course
of this disease. These changes eventually lead to glomer-
ular sclerosis and tubulointerstitial fibrosis.
Pathogenesis of diabetic kidney disease involves a
multifactorial process. Many cohort studies have proven
hyperglycemia as a major risk factor for development
and progression of nephropathy in diabetes. The Diabe-
tes Control and Complications Trial (DCCT) [1] and
United Kingdom Prospective Diabetes Study (UKPDS)
[2] trials demonstrated a significant reduction in the rate
of complications of diabetes, including nephropathy,
with intensive glycemic control in type 1 and type 2
diabetic patients, respectively. High blood glucose con-
centration is capable of activating the protein kinase C
(PKC) system. Chronic hyperglycemia is also associated
with accumulation of advanced glycation end products
(AGE) [3, 4]. Changes in the levels of hormones and
vasoactive peptides, cytokines and growth factors, espe-
cially transforming growth factor- (TGF-) [5] are also
documented in the course of diabetes and play important
roles in the development and progression of diabetic
nephropathy. The reduction in the rate of progression of
kidney disease with the use of the angiotensin-converting
enzyme (ACE) inhibitors in type 1 diabetes [6] and the
angiotensin receptor blockers in type 2 [7, 8] signifies
the importance of the renin-angiotensin system in the
pathogenesis of diabetic nephropathy [9].
Although many therapeutic interventions have post-
poned the development or slowed the progression of
diabetic nephropathy, no intervention to date has been
able to halt or to reverse its progression. This reveals
the complexity of the pathogenic process and mandates
more investigation on the possible role of known patho-
genic factors involved in pathogenesis of other renal
diseases, including inflammatory cytokines.
Tumor necrosis factor- (TNF-) is a 157 amino acid
peptide with a molecular weight of 17 kD. It is produced
mainly by monocytes and macrophages and also by T and
B lymphocytes and glomerular mesangial cells [10, 11].
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TNF- plays an important role in the pathogenesis of
immunological renal diseases, such as lupus nephritis
and anti-glomerular basement membrane (GBM) dis-
ease [12]. Elevated urinary concentrations of TNF- and
its possible intrarenal production have also been demon-
strated in patients with immunoglobulin A (IgA) ne-
phropathy and Henoch-Scho¨nlein purpura [13]. Animal
studies of diabetic kidney disease have demonstrated
increased TNF- mRNA and have suggested a role for
TNF- in the pathogenesis of diabetic nephropathy
[14, 15]. However, there are no studies examining intra-
renal TNF- concentrations and its correlation with
markers of kidney involvement early in the course of
diabetes. In this study, we measured TNF- levels in the
serum, urine and renal interstitial fluids of conscious
rats before and early after induction of diabetes with
streptozotocin (STZ) and examined its correlation with
urinary albumin excretion (UAE).
METHODS
We used microdialysis technique to monitor the
changes in renal interstitial fluid TNF- concentrations.
Diabetes was induced by intravenous injection of STZ
(35 mg/kg) in male Sprague-Dawley rats. We first vali-
dated the accuracy of microdialysis technique in the re-
covery of TNF- in vitro. Then, in the in vivo part of
the study, we measured serum, renal interstitial fluid
and urinary concentrations of TNF- before and after
induction of diabetes. Urine was also monitored for the
UAE rate during the study period.
In vitro study
Preparation of microdialysis catheters has been de-
scribed in details elsewhere [16]. Catheters were pre-
pared by connecting two polyethylene (PE-10) tubes with
a 0.5 cm long dialysis membrane fiber (Filtral 20, Hospal,
Meyzieu, France) with a molecular weight cut-off of 40
to 45 kD. Catheters were immersed in prepared solutions
of TNF- and lactated Ringer’s solution was infused
through the microdialysis catheters. At the other end of
the catheters, samples were collected for 60 minutes and
were examined for TNF- recovery. Absolute recovery
was defined as the absolute rate of recovery of TNF-
per minute of sample collection, and relative recovery as
the percentage of TNF- recovered by the microdialysis
catheter from its solution. First, the absolute and relative
recoveries of TNF- were examined at different lactated
Ringer’s infusion rates of 1, 3, and 5 L/min (N  6 for
each flow rate). The relative recovery of TNF- over a
5-hour period was then checked hourly at an infusion
rate of 3 L/min (N  6). Finally, the relative recovery
of TNF- from solutions with different concentrations
was examined at a constant infusion rate of 3 L/min
(N  6).
Fig. 1. In vitro absolute recovery (AR) and relative recovery (RR) of
tumor necrosis factor- (TNF-) by microdialysis catheter at different
perfusate flow rates of a lactated Ringer’s solution.
In vivo study
After baseline urine and serum (0.5 mL of blood from
the tail vein) sample collections, microdialysis catheters
were placed in the renal cortex (N  13) through a
minor surgery under anesthesia. Four days after catheter
placement, baseline renal interstitial fluid samples were
collected by infusing lactated Ringer’s solution through
the microdialysis catheters at a rate of 3 L/min. Over-
night urine samples were also collected for measurement
of baseline UAE and TNF- levels. One day after base-
line sample collections, and after an overnight fast, eight
rats were injected with 35 mg/kg of STZ into their tail
veins (diabetic group). Renal interstitial fluid samples
were collected by microdialysis technique on days 1, 3,
5, 7, 10, 14, and 17 in the diabetic animals (N  8). In
order to evaluate the influence of inserting the microdia-
lysis catheter in the kidney on TNF-, we monitored
renal interstitial fluid and urinary TNF- levels over 2
weeks in nondiabetic control group (N  5). Overnight
urine samples were collected on days 1, 2, 3, 4, 5, 10, 14,
and 17 in the diabetic group. Serum, urine, and renal
interstitial fluid TNF- concentrations were measured
by enzyme-linked immunosorbent assay (ELISA) using
OptEIA set (Pharmingen, San Diego, CA, USA). UAE
rate was measured by ELISA using Nephrat kit (Exo-
cell, Inc., Philadelphia, PA, USA). Blood glucose con-
centrations were checked on days 1, 7, and 14 after induc-
tion of diabetes using Accu-Chek Advantage glucometer
(Roche, Basel, Switzerland). Body weight was checked
before and after injection of STZ on days 1, 7, and 14.
RESULTS
In vitro recovery of TNF- by microdialysis catheter
The relative recoveries of TNF- from its solution by
the microdialysis catheter at infusion rates of 1, 3, and
5 L/min were 73%, 85%, and 77%, respectively. The
absolute recoveries of TNF- at flow rates of 1, 3, and
5 L/min were 3.2, 11.3, and 16.3 pg/min, respectively
(Fig. 1). Relative recovery of TNF- remained relatively
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Fig. 2. In vitro relative recovery of tumor necrosis factor- (TNF-)
during a 5-hour sample collection at constant lactated Ringer’s perfusion
rate of 3L/min.
constant with more prolonged (5 hours) sample collec-
tion (Fig. 2). The relative recoveries were 85.1%, 77.0%,
84.6%, 79.5%, and 86.4%, for 1 to 5 hours of sample
collection, respectively. Altering concentrations of TNF-
solutions surrounding microdialysis catheters did not af-
fect its relative recovery by the catheter. Relative recov-
ery of TNF- from solutions with concentrations of 265
pg/mL, 200 pg/mL, and 112 pg/mL were 85.1%, 85.7%,
and 88.1%, respectively.
Changes in blood glucose concentrations and body
weight
Development of diabetes was confirmed in all rats by
demonstrating average blood glucose concentrations of
24 1 mmol/L (432.0 17.9 mg/dL), 24.28 1.71 mmol/L
(437.0 30.7 mg/dL), and 31.28 0.31 mmol/L (563.0
5.5 mg/dL) on days 1, 7, and 14 after injection of STZ,
respectively. Average body weight of rats at baseline,
day 7, and day 14 was 266.30 17.27 g, 274.37 23.29 g,
and 294  32.02 g, respectively.
Serum TNF- before and after induction of diabetes
Serum TNF- concentrations were undetectable in the
control and diabetic rats at baseline and throughout the
study.
Renal interstitial fluid TNF- before and after
induction of diabetes
At baseline the renal interstitial fluid TNF- was un-
detectable in samples from 7 of 13 rats with an overall
average of 9.17  3.08 pg/mL [11.96  5.32 pg/mL and
5.97  2.56 pg/mL in diabetic (N  8) and control (N 
5) groups, respectively; P  0.2]. In the control group,
1 and 2 weeks after placement of the microdialysis cathe-
ters, renal interstitial fluid TNF- concentrations were
unchanged compared to baseline (3.33  2.15 pg/mL
and 9.39  4.67 pg/mL, respectively; P  0.5). In the
diabetic group, the changes in the renal interstitial fluid
TNF- concentrations throughout the study are shown
Fig. 3. Renal interstitial fluid tumor necrosis factor- (TNF-) concen-
trations before (day –1) and after (days 1 to 17) induction of diabetes
with streptozotocin (STZ) in rats (N  8). *P  0.04 for comparison
to baseline (day –1).
Fig. 4. Urinary changes in tumor necrosis factor- (TNF-) concentra-
tions during the course of study. Before catheter placement (day –5),
before induction of diabetes with streptozotocin (STZ) (day 1), and
after development of diabetes (days 1 to 21). *P 0. 002 for comparison
with day –1; **P  0.001 for comparison to all days.
in Figure 3. One and 3 days after injection of STZ, TNF-
was still undetectable in the renal interstitial fluid of four
diabetic rats. The average TNF- concentrations for all
diabetic rats (N  8) on days 1 and 3 after induction of
diabetes were 29.45  12.16 pg/mL and 11.94  7.37
pg/mL, respectively. Five days after injection of STZ,
the renal interstitial fluid TNF- concentration showed
a significant rise to 45.02  11.69 pg/mL in all diabetic
animals (P  0.03). Renal interstitial fluid TNF- re-
mained significantly elevated in the diabetic group through-
out the remainder of the study period (P  0.03 for
comparison to baseline and P  0.004 for comparison
to the control group).
Urinary TNF- before and after induction of diabetes
Changes in the urinary concentration of TNF- during
the course of the study are shown in Figure 4. Before
placement of microdialysis catheters TNF- was not de-
tectable in the urine of six rats. Average urinary concen-
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Fig. 5. Urinary albumin excretion (UAE) rate before (day –1) and
after induction of diabetes (days 2 to 17) in rats. (N  8). *P  0.04
for comparison to baseline (day –1).
tration of TNF- at this time was 19.61  7.87 pg/mL
(16.06  6.47 pg/mL in the diabetic and 25.29  18.78
pg/mL in the control group; P 0.6). In the control group,
no significant changes in the concentrations of urinary
TNF- were noticed after 1 and 2 weeks (41.81  17.71
pg/mL and 34.92  20.90 pg/mL, respectively; P  0.5).
On the day before and the day after injection of STZ,
urinary TNF- concentrations in the diabetic animals
were 82.56  23.90 pg/mL and 71.32  4.56 pg/mL,
respectively. Three days after induction of diabetes, the
urinary TNF- concentration showed a significant rise
to 349.65 36.94 pg/mL in all rats (P 0.002 for compar-
ison to baseline and P  0.001 for comparison to con-
trols). This concentration remained elevated thereafter
(P  0.0003 for comparison to the baseline) until day
21 when a second significant rise in the concentration of
urinary TNF- to 638.16  20.54 pg/mL occurred (P 
0.001 for comparison to day 17).
UAE rate
Development of diabetic nephropathy was monitored
by the rate of albumin excretion in the urine as shown
in Figure 5. UAE demonstrated a gradual rise, which
became statistically significant 17 days after induction of
diabetes. At baseline, UAE was 0.56  0.2 g/min and
increased to 8.14  2.98 g/min on day 17 (P  0.01).
UAE rate correlated with renal interstitial fluid (R 
0.73) and urinary TNF- (R  0.75) concentrations in
diabetic rats.
DISCUSSION
Our study demonstrates a significant rise in the urinary
and renal interstitial fluid concentrations of TNF- as
early as 3 days after induction of diabetes in conscious
rats. Almost 2 weeks after the rise in renal cortical and
urinary TNF- levels, the diabetic animals demonstrated
an increase in urinary albumin excretion. The urinary
and renal interstitial fluid concentrations of TNF-
showed a positive correlation with UAE rate. These find-
ings suggest intrarenal production of TNF- in diabetes
and a possible role for it in development of microalbu-
minuria. There was no evidence of lymphocytic infiltrate
of either cortex or medulla in any of the light microscopy
sections (data not shown).
In a recent publication, DiPetrillo, Coutermarsh, and
Gesek [17], using the same model of diabetes, were also
able to demonstrate a significant increase in urinary
TNF- excretion within the first 3 days after induction
of diabetes in rats. Subcutaneous injection of a soluble
TNF receptor fusion protein as an anti-TNF agent in
that study reduced the sodium retention and renal hyper-
trophy in diabetic animals. The authors attributed the
sodium retention seen in diabetic animals to augmented
distal tubular sodium transport in response to elevated
TNF- levels [17].
Nakamura et al [14] were able to demonstrate a sig-
nificant rise in TNF-mRNA expression in the glomeruli
of diabetic rats. TNF- mRNA levels increased by two-
fold after 4 weeks, threefold after 12 weeks, and 4.2-fold
after 24 weeks of diabetes in that study. Treatment with
insulin ameliorated the changes in mRNA levels for
TNF-, TGF-, and other growth factors studied [14]. In
the study of Hasegawa et al [15], incubation of peritoneal
macrophages from normal rats with the GBMs isolated
from diabetic rats as compared to GBMs from normal
rats resulted in a significant rise in the production of TNF-
by macrophages. It has been suggested that accumulation
of AGEs in diabetes could be partly responsible for
the increased production of TNF- by macrophages and
mesangial cells [15]. The activity of macrophages is in-
creased in hypoinsulinemic states, and binding of AGE
to their receptors on these cells, increases TNF- produc-
tion by macrophages [18].
We also found higher concentrations of TNF- in the
urine than in the cortical interstitial fluid suggesting
involvement of other areas of the kidneys, including the
medulla in its production. In normal human kidneys,
the intrarenal gene expressions for TGF-, interleukin-1
(IL-1), and TNF- were found in both cortex and me-
dulla [19]. Cells from the medullary thick ascending limb
of the loop of Henle have been shown to have the capa-
bility of producing TNF-, a process that is augmented
by angiotensin II [20, 21]. Nakamura et al [22] were
also able to demonstrate an increase in glomerular and
medullary levels of TNF- mRNA in nephritic stage of
focal glomerulosclerosis induced by puromycin in rats.
In our study, shortly after the rise in UAE rate, urinary
TNF- concentration showed a further significant in-
crease. This suggests a stimulatory effect for albuminuria
on the production of TNF- by renal tubules. Proximal
tubular cells are capable of producing growth factors
such as TGF- in diabetes. Enhanced protein trafficking
Kalantarina et al: Urinary and renal interstitial concentrations of TNF-1212
in renal tubules is associated with up-regulation of in-
flammatory cytokines and growth factors in proximal
tubular cells [23, 24]. Hyperglycemia is thought to act as
a costimulus to prime these cells for a more pronounced
response to other stimuli [25].
Receptors for TNF- are present on the surface of
virtually all cells examined. Expression of TNF receptors,
TNFR1 and TNFR2, has recently been demonstrated
by immunofluorescence and confocal studies in distal
tubular cells of rat kidneys [17]. Activation of these re-
ceptors by TNF- leads to the activation of multiple
signal transduction pathways, kinases, and transcription
factors, and leads to the activation of an unusual large
array of cellular genes [26]. TNF- is capable of inducing
fibroblast proliferation [27] and procoagulant activity of
endothelium [28] as well as stimulating prostaglandin
production. Therefore, increased TNF- concentrations
could alter glomerular microcirculation [29]. TNF- and
IL-1 have also been associated with increasing vascular
endothelial permeability [30]. Bertani et al [31] were able
to demonstrate a dose dependent injury to the glomer-
ular endothelial cells by intravenous infusion of TNF- in
rabbits.
Finally, Navarro et al [32], in a randomized controlled
study of 24 diabetic patients with advanced renal disease
(creatinine clearance35 mL/min) treated with pentoxi-
fylline (PTF) for 6 months, demonstrated a significant
reduction in serum concentration of TNF- and the level
of proteinuria compared to the control group. Correla-
tion analysis revealed a significant relationship between
proteinuria and plasma levels of TNF-, both at baseline
(r  0.55) and at the end of the study (r  0.57, P 
0.05) [32].
Our data suggest that hyperglycemia and, later on in
the course of diabetic nephropathy, increased protein
trafficking in renal tubules can induce TNF- production
in the kidney. This increase in TNF- concentration
might play a role in the complex pathogenesis of diabetic
nephropathy.
CONCLUSION
Although some studies have demonstrated increased
urinary, in the case of our study, urinary and renal inter-
stitial fluid TNF- concentrations early in the course of
diabetic nephropathy, further studies in animal models
of diabetes are necessary to clarify the significance of
these changes and to examine a causal relationship.
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